Clinical trials: TACE(Transcatheter Arterial Chemoembolization)
Carcinoma, Hepatocellular
Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)
Clinical trial of BAY43-9006 in patients with hepatocellular carcinoma.
- Trial name
- NCT00494299
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 75 sites in Japan, South Korea
- Volunteers
- 458 people
- Sponsor
- Bayer
Carcinoma, Hepatocellular
Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC
The purpose of this study is to determine if TACE plus Sorafenib will improve outcome in patients with advanced hepatocellular carcinoma (HCC) not amenable to surgery.
- Trial name
- NCT00576056
- Testing
- Sorafenib, TACE
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Pittsburgh
Advanced Hepatocellular Carcinoma
Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma
The purpose of this study is to determine whether TAC-101 combined with Transcatheter Arterial Chemoembolization (TACE) is more effective than TACE alone in slowing tumor activity in patients with advanced hepatocellular…
- Trial name
- NCT00667628
- Testing
- TAC-101
- Where
- 29 sites in Japan
- Volunteers
- 54 people
- Sponsor
- Taiho Oncology, Inc.
Hepatocellular Carcinoma
Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.
This research is being done to find out if using the contrast agent MultiHance can be used to show how a liver tumor responds to the chemotherapy given during Transcatheter Arterial Chemoembolization (TACE).
- Trial name
- TACE (NCT00539253)
- Testing
- gadobenate dimeglumine (MultiHance)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hepatocellular Carcinoma, Hepatoma
A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma
This is a prospective, multicenter study that will be conducted at up to 40 centers in the United States and Outside United States (OUS).
- Conditions
- Hepatocellular Carcinoma, Hepatoma, Liver Cell Carcinoma
- Trial name
- SOLACE (NCT02460991)
- Testing
- DEB-TACE, Sorafenib
- Where
- 6 sites in United States
- Volunteers
- 2 people
- Sponsor
- Boston Scientific Corporation
Hepatocellular Carcinoma
Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC
This study will evaluate the role of everolimus in combination with local Transcatheter Arterial Chemoembolization (TACE) procedure in patients with localized unresectable Hepatocellular Carcinoma (HCC).
- Trial name
- TRACER (NCT01379521)
- Testing
- everolimus
- Where
- 5 sites in Hong Kong, Taiwan and 1 more
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma
Accuracy of Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma Post TACE
The purpose of this research study is to find out if a different type of imaging study called contrast enhanced ultrasound (CEUS) is as good as, or better than CT or MRI in patients diagnosed with hepatocellular carcinoma (HCC)…
- Trial name
- TACE (NCT04569799)
- Testing
- Lumason
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Milton S. Hershey Medical Center